longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

NetEase

NTES

117.5600.46% ( +0.540 )
Closed: Sep 24, 15:59:56 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfileWeekly ReviewWeekly Review
LongbridgeAI
Share your thoughts

What's on your mind?

0 / 2,000
  • D
    Dolphin ResearchAug 20 at 01:30 PM

    NTES (Trans): GPM lifted to 70.5%; new titles' reception needs work

    Key takeaways from Netease's 2Q26 earnings call.

    Non-GAAP net profit attributable to shareholders was RMB 7.7bn, down YoY on investment losses. Investment losses were the key drag.

    The July release 'Sea of Remnants' drew heavy negative feedback due to a steep early learning curve. The company is leaning into a 'fewer-but-better' pipeline and AI-driven efficiency. The upcoming title 'Ananta' will be showcased at Gamescom next week.

    S NetEase
    NetEase

    NetEase

    USNTES

    NetEaseConference Minutes
  • D
    Dolphin ResearchAug 20 at 01:07 PM

    NTES: No Cash Burn, Still Riding Legacy Titles; Balance Sheet Stays Strong

    $NTES(09999.HK) $NetEase(NTES.US) released its Q2 2026 results after the HK close on Aug. 20 (Beijing time). The Q2 print was decent. Headline profit appeared to miss, largely due to investment losses.

    Underlying core operations stayed strong, with profit growth supported by a higher mix of self-developed titles and tight cost control. The key drawback remains a thin pipeline, which kept a lid on the top line and was already reflected in deferred revenue in Q2.

    Specifically: 1) slight beat overall. Total revenue was RMB 30.1bn (+8% YoY), driven by the core games biz...

    網易 1 NETEASE
    NetEase (9999.HK/NTES.O) Earnings Results Figures in CNY 100mn 1Q25A 2Q25A 3Q25A
    NetEase Total Revenues CNY 100mn Totalrevenues olphinRese 11.6% IphinResearch -Y
    NetEase Games Revenue CNY 100mn Online games services YoY growth 300 20% 17.5% 2+14
    NetEase

    NetEase

    USNTES

    NetEaseFinancial Analysis
  • D
    Dolphin ResearchAug 20 at 10:24 AM

    NetEase 2Q26 First Take: Q2 results were decent, but headline profit looked like a miss, mainly due to investment losses. Alibaba and PDD fell over 20% in Q2, leading to an approx. RMB 3 bn net loss on the investment portfolio. Ex-portfolio swings, the core OP rose 33% YoY, which is solid.

    Profit growth outpaced revenue as high-GPM self-developed titles took a larger mix, including self-developed PC games such as 'Where Winds Meet‌' and contribution from evergreen franchises. Further helped by tighter S&M and G&A, with lower employee incentives and controlled external UA.

    A weak spot was deferred revenue. While it beat BBG consensus, estimates may have been skewed; on the data, deferred revenue fell 12% QoQ in Q2, wider than typical seasonality.

    Beyond Cloud Music’s impact, this also underscores a lack of new launches. With 'Sea of Oblivion' underperforming and distribution-access tailwinds already played out, the H2 pipeline gap may continue to cap upside.

    On the plus side, high-margin evergreen titles provide a firm floor, and the Apple tax cut offers some incremental benefit. On a low base, NetEase is still positioned to deliver relatively steady performance in H2. $NTES(09999.HK) $NetEase(NTES.US)

    图片 1,共 1 张
    NetEase

    NetEase

    USNTES

  • N
    NewUser_oPJWOUAug 20 at 10:21 AM

    The 3 local banks have stabilised a little following the previous few days of down sessions for the whole SG market. This is good for the longer scheme of things as historical statistics show that steep rise s n share prices are more likely than not followed by steep drawbacks afterwards. Let them consolidate, though I know many are still buying either for long term or just trying to jump on bandwagon.

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Moderna Soars 177% on Landmark Cancer Vaccine Win

    Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...

  • D
    dingdongbellRate Of ReturnAug 20 at 06:59 AM

    Yay! US has shown their intent and are telling the bond market not to have ideas as they will defend yields no matter what FUD the narratives are.

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Moderna Soars 177% on Landmark Cancer Vaccine Win

    Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...

  • N
    NewUser_ThinkSwimAug 20 at 05:04 AM

    Modena stock not certain if its a pump and dump after the news and upside yesterday but generally if you want to invest in healthcare or even in the bio field can consider etf with Modena in it for long term investment. Do not all in money, DCA slowly and see if its temporary demand and expectations issues.

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Moderna Soars 177% on Landmark Cancer Vaccine Win

    Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...

  • H
    Heroic LifesaverTotal AssetsRate Of ReturnAug 20 at 04:35 AM

    It was just a few days ago I mentioned the likelihood of yield curve control and that the US will not sacrifice the stock market at the expense of the bond vigilantes. There were the usual skeptics and rightly so because the textbooks teach you certain things. But the real world is not textbook and the more experienced ones out there will know what I mean. That’s why I keep stating that I am sharing my own opinions and not asking people to agree. 😎

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Moderna Soars 177% on Landmark Cancer Vaccine Win

    Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...

  • T
    TheRaccoonAnalysisTotal AssetsRate Of ReturnAug 20 at 04:34 AM

    Markets are increasingly differentiating between strong AI-related demand and funding or margin concerns. Semiconductor moves highlight shifting competitive dynamics in custom AI chips, while the Fed minutes reinforce uncertainty over the inflation path and potential policy tightening. Consumer results remain mixed, with resilient sales offset by cautious guidance. Nebius’ financing underscores the capital intensity of AI infrastructure and investors’ sensitivity to dilution and funding requirements.

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Moderna Soars 177% on Landmark Cancer Vaccine Win

    Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...

  • L
    LazyCatNVIDIA Return RateGo Beyond!Aug 20 at 03:39 AM

    During Fed chair Warsh's press conference after the Jul meeting, he repeated pointed to the elevated bond yields as a market driven tightening and hence Fed could fold their hands for the moment. However, Treasury secretary Bessent just served the tennis ball back when he announced yesterday that bond buy backs would be minimally doubled. Is Mr Bessent triggering the "test the new Fed chair" rite of passage?

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Moderna Soars 177% on Landmark Cancer Vaccine Win

    Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...

  • D
    DarkwinterAug 20 at 03:36 AM

    177% soar… this sounds like a recipe for pullback… dyodd well

    C
    Captain's Watch
    Featured☕️ [Task Coins Giveaway] Daily Market Talk — Moderna Soars 177% on Landmark Cancer Vaccine Win

    Moderna had its best day ever Wednesday: shares soared 177% after its melanoma vaccine, developed with Merck, became the first mRNA cancer therapy to succeed in a Phase 3 trial. Merck rose alongside i...